Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions

Insuline Medical

Status and phase

Completed

Phase 4

Conditions

Diabetes Mellitus, Type 1

Treatments

Device: InsuPatch

Study type

Interventional

Funder types

Industry

Identifiers

NCT01283425

G080106/B

Details and patient eligibility

About

The study is an open-label, randomized, two-period crossover study. Up to one hundred and twenty (120) subjects with type 1 diabetes mellitus (T1DM) who use the MiniMed paradigm insulin pump, who meet the inclusion/exclusion criteria and who provide written Informed Consent will be enrolled in the study. The aim of the study is to examine the safety of the InsuPatch device in a home use setting. Mild Hypoglycemia,hyperglycemia and Adverse events will be compared between two phases of the study : 3 months with the use of the device and 3 months without the use of the device.

Full description

The primary objective of this study is to show that safety parameters are similar, when delivering insulin subcutaneously in subjects with type I diabetes using the InsuPatch device along with the Medtronic Minimed Paradigm insulin infusion pump and the Medtronic Minimed Quick-Set® infusion set compared to subcutaneous insulin delivered with the above mentioned equipment, without the InsuPatch device.

The participation of each subject in this study will be up to seven months and will include three phases: one week Run in phase , 3 months with device use and 3 months without device use. Study will include 4 clinic visits and bi weekly calls. During the entire study the subjects will be requested to preform at least 5 blood glucose self measurements and record results in a logbook.At each visit blood will be drawn for HBA1C test.

Enrollment

147 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject's age range 18- 65 years old (including 18 and 65 years old)
BMI: 18-35 kg/m2
Type 1 diabetes patients using a MiniMed Paradigm insulin pump for at least six months, who are administering insulin Lispro or Insulin Aspart and are using the Quick-set infusion set.
Patients with T1DM whose HbA1c values are at or below 9.5% (including 9.5%) and at or above 6% (including 6%).
Agree to sign consent form before any study-specific tests or procedures are to be performed.
Subject's completed at least 14 measurements during the Run-In Phase and readiness to continue the study with at least 5 blood glucose recordings per day and keep a logbook during the study period.
Subject readiness to use the InsuPatch, his comprehension of the study requirements and treatment procedures.
Willingness to comply with all specified follow-up evaluations.

Exclusion criteria

Pregnancy
Breast feeding women.
Alcohol addiction
CABG (Coronary Artery Bypass Graft), MI (Myocardial Infarction) or active Ischemic Heart Disease prior to study date.
CVA (cardiovascular accident) or TIA (transient ischemic accident) events prior to study date.
Uncontrolled hypertension (blood pressure in mm HG >160 systolic or > 95 diastolic) .
Any history of gastroparesis or enteroparesis.
Abnormal kidney and/ or liver function tests. (Defined as Creatinine >1.5 mg/dL, liver tests> 2 times the upper limit of normal).
A severe hypoglycemic event requiring a glucagon injection or intravenous glucose infusion within the last six months prior to study inclusion.
Hypoglycemia unawareness.
Diabetic ketoacidosis (severe, with hospitalization) within the last six months prior to study inclusion.
Psychological incompetence.
Signs of drug abuse.
Any other clinical condition or history, which seems to be relevant for the Principle Investigator to disqualify a participant.
Subjects with diminished skin integrity, Excessive fibrosis, lipo-hypertrophy or eczema at infusion sites.
Heat sensitive subjects.
Subjects involved in or planning to participate in other studies.
Subjects using any drug therapy, other than insulin, to control their blood glucose levels.